# Can MOTS-c provide insights into treatment response in multiple myeloma?

Canonical source: https://retacompare.com/research/can-mots-c-provide-insights-into-treatment-response-in-multiple-myeloma

Peptide Longevity Q&A · 2025-11-01


    Research indicates that serum levels of MOTS-c may serve as complementary markers of treatment response in newly diagnosed multiple myeloma. Patients who responded to treatment exhibited significant increases in MOTS-c levels post-therapy, while those who were refractory showed minimal changes.


What the research shows

The study evaluated the role of serum mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) in providing prognostic insights for patients newly diagnosed with multiple myeloma (MM). Conducted as a prospective analysis, the research involved 29 patients diagnosed with MM, measuring serum MOTS-c concentrations before and after frontline treatment. The study systematically explored the associations between fluctuations in MOTS-c levels and various clinical-biochemical variables. Notably, patients who showed a positive response to treatment had a marked increase in MOTS-c levels following therapy, while those who were refractory exhibited little to no change. Furthermore, post-treatment MOTS-c values were found to inversely correlate with changes in calcium and neutrophil counts.


Why it matters for longevity

The findings suggest that MOTS-c dynamics may reflect microenvironmental and metabolic adaptations linked to treatment response in multiple myeloma. While the study indicates that MOTS-c alone may not have strong predictive capabilities, its fluctuations can provide valuable insights into the patient's metabolic state and response to therapy. This understanding is critical as it could lead to improved patient management strategies and potentially enhance overall healthspan, particularly in the context of aging and related diseases. The ability to monitor such biomarkers could help tailor treatments more effectively, thereby supporting better long-term outcomes and longevity in patients.


Key findings at a glance

Serum MOTS-c levels were measured in newly diagnosed multiple myeloma patients.

Patients responding to treatment showed significant increases in MOTS-c levels post-therapy.

Refractory patients exhibited minimal changes in MOTS-c levels.

MOTS-c fluctuations correlated with clinical-biochemical variables, including calcium and neutrophil counts.

MOTS-c may serve as a complementary marker of clinical response in multiple myeloma.

Further validation in larger cohorts is needed to confirm these findings.


How MOTS-c works (background)

MOTS-c is a peptide encoded by mitochondrial DNA, specifically the mitochondrial open reading frame of the 12S rRNA. It plays a role in cellular metabolism and has been implicated in various biological processes, including stress responses and metabolic regulation. In the context of cancer, including multiple myeloma, MOTS-c may influence the tumor microenvironment and metabolic adaptation, potentially impacting treatment efficacy. The dynamics of MOTS-c levels in response to therapy could reflect underlying changes in cellular metabolism, which are crucial for understanding treatment responses and overall disease progression.


Safety, caveats, and what we don't yet know

While the study provides insights into the relationship between MOTS-c levels and treatment response in multiple myeloma, there are limitations to consider. The sample size was relatively small, and further research in larger cohorts is necessary to validate these findings. Additionally, the study focused on a specific patient population, leaving questions about the generalizability of the results to other types of cancers or broader aging contexts. Future studies should explore the mechanisms by which MOTS-c influences treatment outcomes and whether similar patterns are observed in other diseases associated with aging.


Bottom line

Overall, MOTS-c levels may provide valuable insights into treatment response for patients with multiple myeloma, indicating potential adaptations linked to therapy. However, further research is needed to fully understand its implications for longevity and healthspan.


Related questions

How does MOTS-c influence cellular metabolism?

MOTS-c is involved in regulating cellular metabolism, particularly under stress conditions. Its role in metabolic adaptation may be significant in various diseases, including cancer, where metabolic changes can affect treatment responses.

What is the significance of biomarkers in cancer treatment?

Biomarkers like MOTS-c can provide insights into treatment efficacy and disease progression, helping tailor therapies to individual patient needs. This personalization is crucial for improving outcomes in cancer treatment.

Can MOTS-c be used in other age-related diseases?

While the current study focuses on multiple myeloma, the potential of MOTS-c as a biomarker in other age-related diseases remains an area of interest for future research, particularly regarding its role in metabolic regulation.


Source: PubMed · Cureus · published 2025-11-01.

## Sources

- PubMed · Cureus: https://pubmed.ncbi.nlm.nih.gov/41479490/